Drug intelligence / Profile preview

N-(2-(piperidino)ethyl)-2-iodobenzamide

Development stage: Preclinical
Modality: Small Molecules
Administration: Subcutaneous

Overview

N-(2-(piperidino)ethyl)-2-iodobenzamide, also known as 2-IBP, is a small molecule sigma ligand. It demonstrates high-affinity binding to sigma receptors found on small cell lung cancer (SCLC) cell lines, such as NCI-H209 and NCI-N417. In preclinical studies, 2-IBP has been shown to inhibit the proliferation of SCLC cells in vitro and in vivo, and it exhibits localization to SCLC tumors after subcutaneous injection. Its mechanism of action involves targeting sigma receptors, leading to an anti-proliferative effect on cancer cells.

Other names: 125I-N-(2-(piperidino)ethyl)-2-iodobenazmide

Targets

TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on N-(2-(piperidino)ethyl)-2-iodobenzamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-(2-(piperidino)ethyl)-2-iodobenzamide.

Explore the full profile